USPTO Examiner GABEL GAILENE - Art Unit 1678

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19199750METHODS AND DEVICES FROM ISOLATION OF TUMOR CELLSMay 2025January 2026Allow911YesNo
19171004METHODS FOR PERFORMING MINIATURIZED DYNAMIC ASSAYS USING MICROFLUIDICS AND RELATED SYSTEMSApril 2025February 2026Allow1011NoNo
19038526SYSTEMS AND METHODS FOR MEASURING CHANGES IN CELLULAR ACTIVITY IN LIVE TISSUEJanuary 2025July 2025Allow611YesNo
19023243NANO FLUORESCENT LATEX PIGMENT WITH HIGH FLUORESCENCE INTENSITY AND HIGH STABILITY AND PREPARATION METHOD THEREFORJanuary 2025October 2025Allow911NoNo
18918272INDICATOR-BASED ANALYSIS OF A SAMPLEOctober 2024September 2025Allow1111NoNo
18674179Bead-based analysis of a sampleMay 2024January 2025Allow810YesNo
18648822SYSTEM AND METHOD FOR DETECTING, ENUMERATING, OR EXTRACTING MICROORGANISMS IN A SAMPLEApril 2024September 2025Allow1721YesNo
18519724MULTI-SPECTRAL MICROPARTICLE-FLUORESCENCE PHOTON CYTOMETRYNovember 2023December 2025Allow2411NoNo
18375755METHOD FOR GENERATING HIGH AFFINITY ANTIBODIESOctober 2023July 2025Allow2210NoNo
18446969USE OF AN INTEGRATED MICROFLUIDIC CHIP FOR ANALYSIS OF CELL MOTILITY AND PREDICTION AND PROGNOSIS OF PATIENT SURVIVALAugust 2023August 2025Allow2420YesNo
18227151ELISA FOR DIAGNOSIS OF HAEMONCHUS LONGISTIPES INFECTION IN CAMELSJuly 2023February 2024Allow620YesNo
18227030ELISA FOR DIAGNOSIS OF HAEMONCHUS LONGISTIPES INFECTION IN CAMELSJuly 2023December 2023Allow520YesNo
18209814REAGENT COMPOSITION FOR DETECTION OF NON-HEMATOPOIETIC TUMOR AND USE THEREOFJune 2023July 2024Allow1311YesNo
18334185DEVICES AND METHODS OF CELL CAPTURE AND ANALYSISJune 2023February 2026Abandon3311NoNo
18204311COMPOSITIONS AND METHODS FOR PLASMAPHERESISMay 2023March 2025Allow2131YesNo
18200301Bead-based analysis of a sampleMay 2023February 2024Allow910YesNo
18139242MAGNETIC REMOVAL OR IDENTIFICATION OF DAMAGED OR COMPROMISED CELLS OR CELLULAR STRUCTURESApril 2023February 2025Allow2210NoNo
18303725SYSTEMS AND METHODS FOR CYCLIC FLUORESCENCE IMAGINGApril 2023October 2025Allow3011NoNo
18124224METHOD FOR LABELING INTRACELLULAR AND EXTRACELLULAR TARGETS OF LEUKOCYTESMarch 2023May 2025Allow2611YesNo
18120887SYSTEM AND METHOD FOR SAMPLE PRESERVATIONMarch 2023August 2024Allow1711YesNo
18114130METHOD AND SYSTEM FOR BUOYANT-PARTICLE-ASSISTED CELL THERAPYFebruary 2023November 2024Allow2111YesNo
18170852Methods for isolating target cells from bloodFebruary 2023February 2025Abandon2410NoNo
18167557INDICATOR-BASED ANALYSIS OF A SAMPLEFebruary 2023June 2024Allow1621YesNo
17803958Method and Apparatus for Dual Use Microbiology Test CardFebruary 2023February 2026Abandon3610NoNo
18105582COMPOSITIONS AND METHODS FOR PASSIVE OPTICAL BARCODING FOR MULTIPLEXED ASSAYSFebruary 2023March 2025Allow2510YesNo
18164275IMMUNOASSAYS FOR HIGH POSITIVELY CHARGED PROTEINSFebruary 2023June 2025Allow2910YesNo
18040009METHOD OF POOLING SAMPLES FOR ANALYTE DETECTIONJanuary 2023March 2026Abandon3710NoNo
18085476METHODS OF ENUMERATING PARTICLES PRESENT IN A CELL COMPOSITIONDecember 2022July 2025Abandon3110NoNo
18070644Flow Cytometry System and Methods for the Diagnosis of Infectious DiseaseNovember 2022October 2025Allow3521YesNo
17989895MONOCLONAL ANTIBODIES WITH SPECIFICITY FOR FETAL ERYTHROID CELLSNovember 2022March 2025Abandon2820NoNo
17998361ASSAYS FOR THE DETECTION OF A BLOCKING ANALYTENovember 2022November 2024Abandon2401NoNo
18052661FLOW CYTOMETRY EVALUATION OF BIOLOGICAL MATERIAL FOR UNASSOCIATED VIRUS-SIZE PARTICLESNovember 2022November 2024Allow2411YesNo
17971720CYTOMETRIC ASSAYSOctober 2022July 2025Allow3211NoNo
17959725ANTIBODY STAIN WITH LOW FLUOROPHORE RATIO FOR STAINING VIRUS-SIZE PARTICLESOctober 2022August 2024Allow2210YesNo
17916415METHOD FOR DETECTION OF CD16BSeptember 2022February 2026Allow4111YesNo
17945651BIOMARKER TEST AND METHOD FOR ASSESSING MUCOSAL HEALING IN RESPONSE TO TREATMENT OF ULCERATIVE COLITISSeptember 2022March 2025Abandon3020YesNo
17944439PREPARATION OF FETAL NUCLEATED RED BLOOD CELLS (NRBCs) FOR DIAGNOSTIC TESTINGSeptember 2022October 2024Abandon2510NoNo
17941212ELISA FOR DIAGNOSIS OF HAEMONCHUS LONGISTIPES INFECTION IN CAMELSSeptember 2022July 2023Allow1011NoNo
17902102METHODS OF ANALYSIS OF BLOOD FROM DECEASED DONORSSeptember 2022January 2025Abandon2811NoNo
17902095PREPARATION OF FETAL NUCLEATED RED BLOOD CELLS (NRBCS) FOR DIAGNOSTIC TESTINGSeptember 2022December 2024Allow2710YesNo
17898074SPECIMEN ENRICHMENT FOR OPTICAL TOMOGRAPHY CELL ANALYSISAugust 2022April 2025Allow3211YesNo
17886044BIOLOGICAL SAMPLE ANALYSIS METHODAugust 2022November 2025Abandon3910NoNo
17818671ANTIBODIES FOR DETECTION AND ENRICHMENT OF FETAL CELLS AND THEIR USEAugust 2022September 2024Allow2511NoNo
17882835MULTI CHANNEL ISOTHERMAL AMPLIFICATION SYSTEM AND OPERATION METHOD THEREOFAugust 2022March 2026Abandon4301NoNo
17874458BIOLOGICAL SAMPLE ANALYSIS METHODJuly 2022November 2025Abandon4010NoNo
17871775METHOD FOR MEMORY B CELL-SPECIFIC DIFFERENTIATION INDUCTION, AND USES THEREOFJuly 2022March 2026Allow4411YesNo
17813899METHODS AND USES FOR REMOTELY TRIGGERED PROTEASE ACTIVITY MEASUREMENTSJuly 2022June 2025Abandon3510NoNo
17758412METHODS OF ISOLATING A BIOLOGICAL ENTITYJuly 2022December 2023Allow1711NoNo
17856033KIT FOR DETECTING ANTI-PROTEASOME SUBUNIT ALPHA TYPE 1-IMMUNOGLOBULIN G (IgG) ANTIBODYJuly 2022December 2023Abandon1711NoNo
17803380Microbiology test cardJune 2022January 2025Allow3220YesNo
17781498A METHOD OF ISOLATING EXOSOMESJune 2022August 2025Allow3910NoNo
17828177ANALYSIS METHOD AND ANALYSIS DEVICEMay 2022October 2024Allow2910NoNo
17826283KERATIN 17 AS A BIOMARKER FOR BLADDER CANCERMay 2022December 2024Allow3111YesNo
17779608MONOCLONAL ANTIBODY FOR DETECTION OF CAR-T CELLS, KIT AND APPLICATIONMay 2022February 2026Allow4511NoNo
17729528CHO HOST CELL PROTEIN ASSAYApril 2022September 2024Abandon2910NoNo
17721930HYBRID YEAST CELL LINES FOR HIGH LEVEL PRODUCTION OF RECOMBINANT PROTEINApril 2022June 2025Allow3811NoNo
17754452TCR-INDEPENDENT MOLECULAR IDENTIFICATION OF MUTATION-RELATED AND TUMOR-SPECIFIC T CELLSApril 2022November 2025Allow4311YesNo
17655401METHODS AND COMPOSITIONS FOR REMOVING BIOTIN INTERFERENCE FROM ASSAYS USING CONJUGATED MOLECULAR TRAPSMarch 2022June 2024Allow2710NoNo
17677389LABEL-FREE, ON-CHIP DETECTION OF OPIOIDS THROUGH SURFACE-ENHANCED RAMAN SPECTROSCOPYFebruary 2022November 2025Allow4511NoNo
17674967Bead-based analysis of a sampleFebruary 2022May 2023Allow1521YesNo
17650579COMPOSITIONS, KITS, AND METHODS FOR MULTIPLEX ASSAYS TO CORRECT FOR BIOTIN INTERFERENCE IN TARGET ANALYTE MEASUREMENTSFebruary 2022June 2024Allow2810NoNo
17650443METHODS FOR SINGLE MOLECULE ANALYTE DETECTIONFebruary 2022November 2022Allow1011YesNo
17667153METHOD FOR THE FORMATION AND USE OF AN IMMUNOLABELING COMPLEXFebruary 2022May 2025Allow3911YesNo
17633423METHOD AND FLOW CYTOMETER FOR EXAMINING A HUMAN OR ANIMAL CELL SPECIMEN, AND COMPUTER PROGRAM PRODUCTFebruary 2022October 2025Abandon4401NoNo
17589067CHO HOST CELL PROTEIN ASSAYJanuary 2022September 2024Allow3110NoNo
17569551Method for Magnetically Labeling Particles and Labeling ApparatusJanuary 2022May 2025Allow4010YesNo
17596950Method of Identifying Pro-Inflammatory Dendritic CellsDecember 2021December 2025Allow4711YesNo
17618553PROGNOSIS PREDICTION METHOD OF IDIOPATHIC PULMONARY FIBROSISDecember 2021September 2025Abandon4501NoNo
17513080ISOLATION OF CELLS OF EPITHELIAL ORIGIN CIRCULATING IN PERIPHERAL BLOODOctober 2021April 2024Abandon3001NoNo
17451029EXTENDED RANGE IMMUNOASSAY DEVICES WITH IMMUNOSENSOR AND MAGNETIC IMMUNOSENSOROctober 2021December 2025Allow5011YesNo
17501784METHOD FOR PREDICTING AND MONITORING CLINICAL RESPONSE TO IMMUNOMODULATORY THERAPYOctober 2021April 2024Allow3011YesNo
17491424METHODS FOR MEASURING UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 LEVELS IN BLOODSeptember 2021June 2024Allow3310YesNo
17469225TISSUE STAINING METHOD, TISSUE EVALUATION METHOD AND BIOSUBSTANCE DETECTION METHODSeptember 2021March 2024Abandon3010NoNo
17466654DEVICES AND METHODS FOR MAGNETIC ISOLATION AND ANALYSIS OF RARE CELLSSeptember 2021April 2025Abandon4311NoNo
17409478Bead-based analysis of a sampleAugust 2021August 2025Allow4831YesYes
17406324Compositions and Methods to Detect Non-Coeliac Gluten SensitivityAugust 2021September 2025Abandon4921YesNo
17388223METHOD FOR MEASURING IMMUNOSTIMULATORY RESPONSE OF IMMUNE CELL, METHOD FOR DETERMINING ABILITY TO FORM IMMUNE SYNAPSE IN IMMUNE CELL, AND CELL ANALYZERJuly 2021June 2023Allow2310NoNo
17366233ANALYTE DETECTION AND METHODS THEREFORJuly 2021December 2024Allow4121YesNo
17414788METHOD FOR SELECTING BIOLOGICAL BINDING MOLECULESJune 2021January 2023Allow1910NoNo
17349682UPCONVERSION FOR MICROSCOPYJune 2021April 2023Allow2221YesNo
17349710INDICATOR-BASED ANALYSIS OF A SAMPLEJune 2021November 2022Allow1721YesNo
17325681ASSAYS FOR THE DETECTION OF A BLOCKING ANALYTEMay 2021January 2023Allow2032NoNo
17324685POLYCLONAL-MONOCLONAL ELISA ASSAY FOR DETECTING N-TERMINUS PRO-BNPMay 2021August 2024Abandon3910NoNo
17294183IMMUNOCHROMATOGRAPHIC TEST STRIP AND IMMUNOCHROMATOGRAPHIC DETECTION KITMay 2021April 2025Allow4711YesNo
17307127COMPOSITIONS AND METHODS FOR PASSIVE OPTICAL BARCODING FOR MULTIPLEXED ASSAYSMay 2021November 2022Allow1911YesNo
17234182IDENTIFICATION OF PLATELET ACTIVATING ANTIBODIESApril 2021April 2025Allow4812YesNo
17277912GLYCATED HEMOGLOBIN (%) ASSAY METHODMarch 2021August 2024Abandon4101NoNo
17276226METHOD OF DYNAMICS ANALYSIS FOR COMPOUND IN CELLMarch 2021April 2025Abandon4901NoNo
17250844BIOMARKERS FOR TYPE 1 DIABETESMarch 2021September 2025Abandon5411NoNo
17195416Methods, Reagents and Kits for Flow Cytometric ImmunophenotypingMarch 2021April 2024Allow3711YesNo
17182859Activated GTPase-Based Assays and Kits for the Diagnosis of Sepsis and Other InfectionsFebruary 2021March 2025Allow4812NoNo
17174917METHOD OF DETERMINING THE PRESENCE AND/OR AMOUNT OF TARGET MOLECULESFebruary 2021April 2025Allow5021YesNo
17263800METHODS, KITS AND STAIN COMPOSITIONS FOR FLOW CYTOMETRY EVALUATION OF UNASSOCIATED VIRUS-SIZE PARTICLES USING MULTIPLE FLUOROGENIC DYESJanuary 2021September 2024Allow4311YesNo
17148153SIMPLIFIED NUCLEI ANALYSIS PLATFORM AND BIOMARKER MATRIX THAT SUPPORTS GENOTOXIC MODE OF ACTION DETERMINATIONSJanuary 2021July 2023Allow3010NoNo
17250347METHODS FOR DETECTION OF ABERRANT RESULTS CAUSED BY INCOMPLETE DISPERSION OF IMMUNOASSAY REAGENTJanuary 2021January 2025Allow4820NoNo
17143463HDL-ASSOCIATED PROTEIN BIOMARKER PANEL DETECTIONJanuary 2021March 2025Allow5021NoNo
17139815Paired Microparticles-Based Kits for Detecting AnalytesDecember 2020August 2023Allow3110YesNo
17132380ASSAY METHODSDecember 2020August 2024Allow4320YesNo
17130398FLOW CYTOMETRY FOR MONITORING HISTONE H3 METHYLATION STATUSDecember 2020April 2024Abandon4001NoNo
17255118Methods for Detecting Cancer-Related Cell Populations, Screening for Metastatic Cancer and Treatments ThereofDecember 2020November 2025Abandon5921NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GABEL, GAILENE.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
0
(0.0%)
Examiner Reversed
1
(100.0%)
Reversal Percentile
91.6%
Higher than average

What This Means

With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
30
Allowed After Appeal Filing
12
(40.0%)
Not Allowed After Appeal Filing
18
(60.0%)
Filing Benefit Percentile
65.0%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner GABEL, GAILENE - Prosecution Strategy Guide

Executive Summary

Examiner GABEL, GAILENE works in Art Unit 1678 and has examined 492 patent applications in our dataset. With an allowance rate of 77.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner GABEL, GAILENE's allowance rate of 77.0% places them in the 44% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by GABEL, GAILENE receive 1.99 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GABEL, GAILENE is 38 months. This places the examiner in the 29% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +43.5% benefit to allowance rate for applications examined by GABEL, GAILENE. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 33.0% of applications are subsequently allowed. This success rate is in the 71% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 52.9% of cases where such amendments are filed. This entry rate is in the 79% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 160.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 90% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 96.3% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 88.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 72.8% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 13.2% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.